Results 41 to 50 of about 8,708 (251)
Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles [PDF]
, 2017 Background: We assessed the activity of ceftolozane/tazobactam against consecutive isolates collected in the BSAC Bacteraemia Surveillance from 2011 to 2015 and against ‘problem’ isolates sent to the UK national reference laboratory from July 2015, when ...
Aiysha Chaudhry +43 more
core +1 more source
Ceftolozane-tazobactam in nosocomial pneumonia
Revista Española de Quimioterapia, 2022 Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the ...
Candel, Francisco Javier +3 more
openaire +2 more sources
International Journal of Infectious Diseases, 2021 : Objectives: To report on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates collected from hospitalized patients with pneumonia in US intensive care units (ICUs) between 2015 and 2018. Activity against all P.
Michael A. Pfaller +7 more
doaj +1 more source
Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains [PDF]
, 2015 Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection
Burnham, Carey-Ann D +4 more
core +2 more sources
The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group [PDF]
, 2018 Expedited pathways to antimicrobial agent approval by the U.S. Food and Drug Administration (FDA) have led to increased delays between drug approval and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices.
Burnham, Carey-Ann D +6 more
core +2 more sources
Shifting Gears: The Future of Polymyxin Antibiotics
Antibiotics, 2019 The manuscripts contained in this special edition of Antibiotics represent a current review of the polymyxins as well as highlights from the 3rd International Polymyxin Conference, which was held in Madrid, Spain, 25 to 26 April 2018.
Justin R. Lenhard +3 more
doaj +1 more source
, 2017 Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using
Roland, Will
core +1 more source
Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess
Clinical Case Reports, 2018 Key Clinical Message Treatment of Pseudomonas aeruginosa remains challenging, despite the availability ceftolozane‐tazobactam. We report a treatment failure with ceftolozane‐tazobactam salvage therapy for pneumonia complicated by lung abscess.
Paul O. Lewis +4 more
doaj +1 more source
mBio, 2018 Pseudomonas aeruginosa produces a class C β-lactamase (e.g., PDC-3) that robustly hydrolyzes early generation cephalosporins often at the diffusion limit; therefore, bacteria possessing these β-lactamases are resistant to many β-lactam antibiotics.
Melissa D. Barnes +11 more
doaj +1 more source
Antibiotics, 2022 Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections.
Aisling R. Caffrey +7 more
doaj +1 more source